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Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids was requested to
evaluate 53 ﬂavouring substances attributed to the Flavouring Group Evaluation 07, including four new
substances but-3-en-2-ol, non-1-en-e-ol, hex-1-en-3-one and 1-nonene-3-one [FL-nos: 02.131, 02.187,
07.161 and 07.210] in this Revision 5, using the Procedure in Commission Regulation (EC) No 1565/2000.
None of the 53 substances was considered to have genotoxic potential. The substances were evaluated
through a stepwise approach that integrates information on the structure–activity relationships, intake
from current uses, toxicological threshold of concern (TTC), and available data on metabolism and
toxicity. The Panel concluded that all 53 substances do not give rise to safety concerns at their levels of
dietary intake, estimated on the basis of the ‘Maximised Survey-derived Daily Intake’ (MSDI) approach.
Besides the safety assessment of the ﬂavouring substances, the speciﬁcations for the materials of
commerce have also been considered and found adequate. For 50 substances, further information is
required based on comparison of the ‘modiﬁed Theoretical Added Maximum Daily Intakes’ (mTAMDIs)
with the TTCs. This would include more reliable intake data and then, if required, additional toxicological
data.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The use of ﬂavourings is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and Council of 16 December 20081 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
On 27 September 2012, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids adopted an opinion on Flavouring Group Evaluation 205 (FGE.205): consideration of
genotoxic potential on a,b-unsaturated aliphatic ketones with terminal double bonds and precursors
from chemical subgroup 1.2.2 of FGE.19.
The Panel concluded that for the two representative substances, oct-1-en-3-one [FL-no: 07.081]
and pent-1-en-3-one [FL-no: 07.102], the positive effects in the bacterial mutagenicity assays cannot
be overruled by one negative and one equivocal gene mutation test in mammalian cells. Accordingly,
an in vivo Comet assay on the ﬁrst site of contact (e.g. the stomach or duodenum) and on the liver is
requested for the most potent substance, pent-1-en-3-one. As an alternative, a transgenic animal
assay would also be acceptable.
On 10 March 2015, the applicant submitted additional studies on the representative substances
[FL-no: 07.102] and [FL-no: 07.081]. These studies are intended to cover the substances in this group,
namely: FL-nos: 02.023, 02.099, 02.104, 02.131, 02.136, 02.155, 02.187, 07.161, 07.210, 09.281 and
09.282.
1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority (EFSA) to evaluate the
new information and, depending on the outcome, proceed to the full evaluation on the ﬂavouring
substances in accordance with Commission Regulation (EC) No 1565/20003.
1.1.3. Interpretation of the terms of reference
In FGE.205 Revision 1, EFSA evaluated the additional data on genotoxicity submitted for the
substances, oct-1-en-3-one [FL-no: 07.081] and pent-1-en-3-one [FL-no: 07.102], by the ﬂavour
industry. For these substances, being the representative of four of the ﬂavouring substances in FGE.07,
the Panel concluded that the concern for a genotoxic potential could be ruled out. As a follow up to
this conclusion, the substances, but-3-en-2-ol [FL-no: 02.131], non-1-en-e-ol [FL-no: 02.187], hex-1-
en-3-one [FL-no: 07.161] and 1-nonene-3-one [FL-no: 07.210], were evaluated by the Panel in
accordance with the Procedure described in Commission Regulation (EC) No 1565/20003, in line with
the background and terms of references as provided by the European Commission.
1.1.4. History of the evaluation
The ﬁrst version of the Flavouring Group Evaluation 07, FGE.07, dealt with 35 saturated and
unsaturated aliphatic secondary alcohols, ketones and esters with secondary alcohol moiety.
The ﬁrst revision of FGE.07, FGE.07Rev1, included the assessment of six additional ﬂavouring
substances [FL-nos: 02.190, 07.162, 07.201, 07.236, 07.676 and 09.926]. No new data on toxicity
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. Ofﬁcial Journal of the European Communities 19.7.2000, L
180, p. 8–16.
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were provided. For two of the new substances, [FL-nos: 07.162 and 07.201], data on metabolism were
provided. Additional information on 20 ﬂavouring substances [FL-nos: 02.124, 02.142, 02.148, 02.177,
02.182, 02.183, 07.156, 07.157, 07.182, 07.185, 07.205, 09.304, 09.323, 09.325, 09.328, 09.332,
09.386, 09.388, 09.391 and 09.880] was made available since the FGE.07 was published.
The second revision of FGE.07, FGE.07Rev2, included the assessment of two additional ﬂavouring
substances [FL-nos: 02.255 and 07.239]. No new data on toxicity and metabolism were provided.
The third revision of FGE.07, FGE.07Rev3, included the assessment of one additional candidate
substance [FL-nos: 07.262]. Toxicity data (acute toxicity, 28-days study and an Ames test) were
submitted. No metabolism data were provided for this substance. A search in open literature did not
provide any further data on toxicity or metabolism for this substance. Furthermore additional
information on the speciﬁcations for eight candidate substances requested in FGE.07Rev2 had been
submitted by industry and included in this FGE.
The fourth revision of FGE.07, FGE.07Rev4, included the assessment of ﬁve additional candidate
substances [FL-nos: 02.145, 02.194, 02.211, 07.198 and 07.204]. These substances had been
considered with respect to genotoxicity in FGE.206 (EFSA CEF Panel, 2011) and the Panel concluded
that the data available ruled out the concern for genotoxicity and accordingly the substances could be
evaluated through the Procedure.
FGE Adopted Link Substances
FGE.07 9.12.2004 http://www.efsa.europa.eu/en/scdocs/scdoc/164.htm 35
FGE.07Rev1 26.9.2007 http://www.efsa.europa.eu/en/scdocs/scdoc/722.htm 41
FGE.07Rev2 26.3.2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1020.htm 43
FGE.07Rev3 30.9.2010 http://www.efsa.europa.eu/en/efsajournal/pub/1845.htm 44
FGE.07Rev4 27.9.2012 http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2012.2899/full 49
FGE.07Rev5 1.2.2017 http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4725/full 53
The present revision of FGE.07, FGE.07Rev5 includes the assessment of four additional candidate
substances [FL-nos: 02.131, 02.187, 07.161 and 07.210]. These substances had been considered with
respect to genotoxicity in FGE.205Rev1 (EFSA CEF Panel, 2016). Based on new genotoxicity data
submitted by the ﬂavour industry, the Panel concluded that the concern for genotoxicity could be ruled
out, and therefore, the four substances could be evaluated through the Procedure in FGE.07Rev5.
A search in open literature for these four new substances conducted for metabolism and toxicity did
not reveal any pertinent new information.
2. Assessment
2.1. Presentation of the substances in FGE.07Rev5
2.1.1. Identity of the substances
The present Flavouring Group Evaluation 7, Revision 5 (FGE.07Rev5), using the Procedure as
referred to in the Commission Regulation (EC) 1565/2000 (the Procedure – shown in schematic form in
Appendix A), deals with 53 saturated and unsaturated aliphatic acyclic secondary alcohols, ketones
and esters with a secondary alcohol moiety. These 53 ﬂavouring substances belong to the chemical
group 5 of Annex I of Commission Regulation (EC) No 1565/20003.
The 53 ﬂavouring substances (candidate substances) are closely related to 67 ﬂavouring substances
(supporting substances) evaluated at the 51st, 59th and 69th meetings of the Joint FAO/WHO Expert
Committee on Food Additives (JEFCA) in the group ‘Saturated Aliphatic Acyclic Secondary Alcohols,
Ketones, and Related Saturated and Unsaturated Esters’ (JECFA, 2000a, 2002a, 2003, 2009b).
The 53 candidate substances under consideration in the present evaluation are listed in Table 1, as
well as their chemical Register names, FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of
Europe- (CoE-) and Flavor and Extract Manufacturers Association- (FEMA-) numbers, and structures.
Seven ﬂavouring substances are saturated aliphatic acyclic secondary alcohols [FL-nos: 02.077,
02.142, 02.148, 02.177, 02.182, 02.183 and 02.190]; seven are unsaturated aliphatic secondary
alcohols [FL-nos: 02.124, 02.131, 02.145, 02.187, 02.194, 02.211 and 02.255] of which ﬁve contain a
terminal double bond [FL-nos: 02.131, 02.145, 02.187, 02.194 and 02.211]; 13 are saturated aliphatic
ketones [FL-nos: 07.072, 07.084, 07.150, 07.157, 07.158, 07.160, 07.178, 07.181, 07.182, 07.185,
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07.189, 07.199 and 07.205]; 10 are unsaturated aliphatic ketones [FL-nos: 07.156, 07.161, 07.162,
07.198, 07.201, 07.204, 07.210, 07.236, 07.239 and 07.262] of which seven contain a terminal double
bond [FL-nos: 07.161, 07.162, 07.201, 07.204, 07.210, 07.239 and 07.262] and 16 are esters of
aliphatic acyclic secondary alcohols and linear or branched-chain aliphatic carboxylic acids [FL-nos:
09.304, 09.323, 09.325, 09.328, 09.332, 09.386, 09.388, 09.391, 09.604, 09.605, 09.606, 09.608,
09.609, 09.676, 09.880 and 09.926].
The hydrolysis products of the candidate esters are listed in Appendix B, Table B.2.
The names and structures of the 67 supporting substances are listed in Appendix B, Table B.3,
together with their evaluation status (CoE, 1992; SCF, 1995; JECFA, 1999a, 2002a, 2003, 2009b).
2.1.2. Stereoisomers
It is recognised that geometrical and optical isomers of substances may have different properties.
Their ﬂavour may be different; they may have different chemical properties resulting in possible
variability in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must
be provided on the conﬁguration of the ﬂavouring substance, i.e. whether it is one of the geometrical/
optical isomers, or a deﬁned mixture of stereoisomers. The available speciﬁcations of purity will be
considered in order to determine whether the safety evaluation carried out for candidate substances
for which stereoisomers may exist can be applied to the materials of commerce. Flavouring substances
with different conﬁgurations should have individual chemical names and codes (CAS number, FLAVIS
number, etc.).
Twenty-seven candidate substances possess a chiral centre [FL-nos: 02.124, 02.131, 02.142,
02.145, 02.148, 02.177, 02.183, 02.187, 02.190, 02.194, 02.211, 02.255, 07.157, 07.182, 07.185,
07.239, 09.304, 09.323, 09.325, 09.328, 09.332, 09.386, 09.388, 09.391, 09.676, 09.880 and 09.926]
and two of the candidate substances possess two chiral centres [FL-nos: 02.182 and 07.205]
(see Table 1).
Due to the presence and the position of double bonds, 10 candidate substances can exist as
geometrical isomers [FL-nos: 02.145, 02.194, 02.211, 02.255, 07.156, 07.198, 07.236, 07.239, 09.386
and 09.880]. (EFFA, 2010; EFFA, 2012) (see Table 1).
2.1.3. Speciﬁcations
Purity criteria for all 53 candidate substances have been provided by the ﬂavour industry (EFFA,
2002a,c, 2007c; Flavour Industry, 2006,2009). Judged against the requirements in Annex II of
Commission Regulation (EC) No 1565/20003, the information is adequate for all candidate substances
(EFFA, 2010, 2012, 2016, 2017) (see Section 2.1.2 and Table 1). Adequate speciﬁcations including
purity and identity for the materials of commerce have been provided for all the candidate substances.
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2.1.4. Natural occurrence in food
Forty-ﬁve of the candidate substances have been reported to occur naturally. These occurrences
include among others: milk and milk products as cheese of various types, beef, chicken, guinea hen,
lamb and mutton, ﬁsh, oysters, scallops and shrimps, passion fruit, plum, papaya, strawberry, citrus
fruits, apples, hop oil, camomile, tomatoes and potatoes, cocoa and tea, maize, nuts and different
alcoholic beverages. The highest quantiﬁed natural occurrences in foods are presented in Table 2 (full
data set are available in Appendix F).
For eight candidate substances listed in Table 3 no natural occurrence data have been identiﬁed
(VCF online, 2016).
2.2. Intake data
Annual production volumes of the ﬂavouring substances as surveyed by industry can be used to
calculate the ‘Maximised Survey-derived Daily Intake’ (MSDI) by assuming that the production ﬁgure
only represents 60% of the use in food due to underreporting and that 10% of the total European
Union (EU) population are consumers (SCF, 1999).
However, the Panel noted that due to year-to-year variability in production volumes, to
uncertainties in the underreporting correction factor and to uncertainties in the percentage of
consumers, the reliability of intake estimates on the basis of the MSDI approach is difﬁcult to assess.
The Panel also noted that in contrast to the generally low per capita intake ﬁgures estimated on the
basis of this MSDI approach, in some cases, the regular consumption of products ﬂavoured at use
levels reported by the ﬂavour industry in the submissions would result in much higher intakes. In such
cases, the human exposure thresholds below which exposures are not considered to present a safety
concern might be exceeded.
Considering that the MSDI model may underestimate the intake of ﬂavouring substances by certain
groups of consumers, the Scientiﬁc Committee on Food (SCF) recommended also taking into account
the results of other intake assessments (SCF, 1999).
One of the alternatives is the ‘Theoretical Added Maximum Daily Intake’ (TAMDI) approach, which
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for ﬂavourable
beverages and foods in general, with exceptional levels for particular foods. This method is regarded
as a conservative estimate of the actual intake by most consumers because it is based on the
assumption that the consumer regularly eats and drinks several food products containing the same
ﬂavouring substance at the upper use level.
Table 2: Candidate substances reported to occur naturally in food (VCF online 2016)
FL-no Name Quantitative data reported
02.077 Pentan-3-ol Up to 34 mg/kg in tea
02.124 6-Methylhept-5-en-2-ol Up to 50 mg/kg in citrus fruits
02.145 2,6-Dimethylocta-1,5,7-trien-3-ol Up to 100 mg/kg in sage
07.084 Pentan-3-one Up to 14 mg/kg in mushroom
09.323 sec-Butyl acetate Up to 67 mg/kg in vinegar
09.391 sec-Heptyl hexanoate Up to 6,634 mg/kg in passion fruit
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One option to modify the TAMDI approach is to base the calculation on normal rather than upper
use levels of the ﬂavouring substances. This modiﬁed approach is less conservative (e.g. it may
underestimate the intake of consumers being loyal to products ﬂavoured at the maximum use levels
reported). However, it is considered as a suitable tool to screen and prioritise the ﬂavouring substances
according to the need for reﬁned intake data (EFSA, 2004).
2.2.1. Estimated daily per capita intake (MSDI approach)
The intake estimation is based on the MSDI approach, which involves the acquisition of data on the
amounts used in food as ﬂavourings (SCF, 1999). These data are derived from surveys on annual
production volumes in Europe. These surveys were conducted in 1995 by the International
Organization of the Flavour Industry (IOFI), in which ﬂavour manufacturers reported the total amount
of each ﬂavouring substance incorporated into food sold in the EU during the previous year (IOFI,
1995). The intake approach does not consider the possible natural occurrence in food.
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is
consumed by 10% of the population4 (Eurostat, 1998). This is derived for candidate substances from
estimates of annual volume of production provided by industry and incorporates a correction factor of
0.6 to allow for incomplete reporting (60%) in the industry surveys (SCF, 1999).
In the present (FGE.07Rev5, the total annual volume of production of the 53 candidate substances
for use as ﬂavouring substances in Europe has been reported to be approximately 690 kg (EFFA,
2002b,c, 2007c; Flavour industry, 2009) and for 64 of the 67 supporting substances approximately
750,000 kg (isopropyl alcohol accounts for 690,000 kg and acetone for 50,000 kg) (cited by the JECFA
(1999a). For three supporting substances, no EU annual volumes of production are available (JECFA,
2003; IOFI, 1995) (Tables 4 and B.3).
On the basis of the annual volumes of production reported for the 53 candidate substances, the daily
per capita intakes for each of these ﬂavourings have been estimated (Table B.1). Approximately 90% of
the total annual volume of production for the candidate substances (EFFA, 2002b, 2007c) is accounted
for by one candidate substance, 9-decen-2-one [FL-no: 07.262]. The estimated daily per capita intake of
this candidate substance from use as a ﬂavouring substance is 73 lg/capita per day. The daily per capita
intakes for each of the remaining substances is less than 2 lg/capita per day (Table B.1).
2.2.2. Intake estimated on the basis of the modiﬁed TAMDI (mTAMDI)
The method for calculation of modiﬁed Theoretical Added Maximum Daily Intake (mTAMDI) values
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may
consume a certain amount of ﬂavourable foods and beverages per day.
For the present evaluation of the 53 candidate substances, information on food categories and
normal and maximum use levels,5,6,7 were submitted by the ﬂavour industry (EFFA, 2002a,c, 2007a,b,c;
Table 4: Tonnage data and MSDI for candidate and supporting substances
Tonnage (kg/year) MSDI (lg/capita per day)

















Total 742,882 11,735 90,450 1,430
MSDI: Maximised Survey-derived Daily Intake.
4 EU ﬁgure 375 million. This ﬁgure relates to EU population at the time for which production data are available, and is consistent
(comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for the enlarged
EU (Eurostat, 1998).
5 ’Normal use’ is deﬁned as the average of reported usages and’maximum us’ is deﬁned as the 95th percentile of reported
usages (EFFA, 2002d).
6 The normal and maximum use levels in different food categories have been extrapolated from ﬁgures derived from 12 model
ﬂavouring substances (EFFA, 2004).
7 The use levels from food category 5’Confectionery’ have been inserted as default values for food category 14.2’Alcoholic
beverages’ for substances for which no data have been given for food category 14.2 (EFFA, 2007a).
Flavouring Group Evaluation 07 Revision 5
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2017;15(3):4725
Flavour Industry, 2006, 2009, EFFA, 2016). The 53 candidate substances are used in ﬂavoured food
products divided into the food categories, outlined in Annex III of the Commission Regulation (EC) No
1565/20003, as summarised in Table 5. For the present calculation of mTAMDI, the reported normal use
levels were used. In the case where different use levels were reported for different food categories, the
highest reported normal use level was used.
According to the ﬂavour industry, the normal use levels for the 53 candidate substances are in the
range of 1–30 mg/kg food, and the maximum use levels are in the range of 5–150 mg/kg (EFFA,
2002a,b,c,d, 2007a,b,c, 2016; Flavour Industry, 2006, 2009).
The mTAMDI values for the 28 candidate substances from structural class I (see Section 2.4) range
from 1,600 to 3,900 lg/person per day. For the 25 candidate substance from structural class II, the
mTAMDI range from 1,500 to 6,600 lg/person per day.
For detailed information on use levels and intake estimations based on the mTAMDI approach, see
Appendix C.
2.3. Absorption, distribution, metabolism and excretion
In general, aliphatic secondary alcohols and ketones are expected to be rapidly absorbed in the
gastrointestinal tract. The candidate aliphatic esters are expected to be hydrolysed enzymatically to
their component secondary alcohols and carboxylic acids. The carboxylic acids are completely oxidised
in the fatty acid pathway and the tricarboxylic acid pathway (see Appendix D).
Secondary alcohols may undergo oxidation to the corresponding ketone; however, in the in vivo
situation, the alcohol is removed from the equilibrium by conjugation to glucuronic acid, which
represents the major pathway of metabolism for secondary alcohols. The glucuronides of the
candidate secondary alcohols are expected to be eliminated via the urine (Felsted and Bachur, 1980;
Kasper and Henton, 1980; JECFA, 1999a).





01.0 Dairy products, excluding products of category 2 All
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except [FL-no: 07.262]
03.0 Edible ices, including sherbet and sorbet All
04.1 Processed fruits All
04.2 Processed vegetables (including mushrooms & fungi,
roots & tubers, pulses and legumes), and nuts & seeds
Only [FL-no: 07.262]
05.0 Confectionery All except [FL-no: 07.205]
06.0 Cereals and cereal products, including ﬂours & starches
from roots & tubers, pulses & legumes, excluding bakery
All except [FL-nos: 02.255 & 07.262]
07.0 Bakery wares All except [FL-no: 07.262]
08.0 Meat and meat products, including poultry and game All except [FL-nos: 02.255 & 07.262]
09.0 Fish and ﬁsh products, including molluscs, crustaceans
and echinoderms
All except [FL-nos: 09.608, 02.255 &
07.262]
10.0 Eggs and egg products None
11.0 Sweeteners, including honey None
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-nos: 07.156, 02.255 &
07.262]
13.0 Foodstuffs intended for particular nutritional uses All
14.1 Non-alcoholic (‘soft’) beverages, excl. dairy products All
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic
counterparts
All except [FL-no: 07.205]
15.0 Ready-to-eat savouries All except [FL-nos: 02.255, 07.157,
09.609 & 07.262]
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) –
foods that could not be placed in categories 1–15
All
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In general, the major metabolic pathway for aliphatic ketones is reduction of the ketone to the
corresponding secondary alcohol and subsequent excretion as glucuronic acid conjugate (Felsted and
Bachur, 1980; JECFA, 1999a).
Short-chain ketones (C < 5) that contain a carbonyl function at the C2 position may undergo
oxidation to yield an alpha-keto carboxylic acid, which through decarboxylation will be oxidised to
carbon dioxide and a simple aliphatic carboxylic acid that will enter the fatty acid pathway and citric
acid cycle (Dietz et al., 1981). Ketones may also be metabolised by omega- or omega-1-oxidation
yielding a hydroxy-ketone that may be further reduced to a diol and excreted in the urine as
glucuronic acid conjugate. Longer chain aliphatic ketones (C ≥ 5) are primarily metabolised via
reduction, but omega- and omega-1-oxidation are competing pathways at high concentrations (Dietz
et al., 1981; Topping et al., 1994).
Omega-1-oxidation of certain aliphatic ketones may yield gamma-diketones, which may give rise to
neuropathy of giant-axonal type. The metabolic pathway includes oxidation of the omega-1-carbon,
ﬁrst to a hydroxy-ketone and then to a diketone. The gamma-spacing of the carbonyl functions has
been shown to be a prerequisite for neurotoxic effects, thus, only ketones with this structural feature
may yield the neurotoxic metabolites. Neurotoxic effects are, however, only observed at relatively high
dosages (Topping et al., 1994). One of the candidate substances, 5-methylheptan-3-one [FL-no:
07.182], may potentially be oxidised to a gamma-diketone.
Twelve of the candidate substances, but-3-en-2-ol, 2,6-dimethylocta-1,5,7-triene-3-ol, non-1-en-3-
ol, octa-1,5-dien-3-ol, undeca-1,5-dien-3-ol, hex-1-en-3-one, hex-5-en-2-one, tridec-12-en-2-one,
3,3,6-trimethylhepta-1,5-dien-4-one, 1-nonene-3-one, ([R-(E)]-5-isopropyl-8-methylnona-6,8-dien-2-
one and 9-decen-2-one [FL-nos: 02.131, 02.145, 02.187, 02.194, 02.211, 07.161, 07.162, 07.201,
07.204, 07.210, 07.239 and 07.262] have terminal double bonds. These double bonds may be oxidised
to the corresponding epoxides. Epoxides are highly reactive molecules, due to the large strain
associated with this three-membered ring structure, and they react easily with nucleophilic sites of
cellular macromolecules. However, epoxides will be conjugated with glutathione by glutathione
S-transferases or hydrolysed to diols by epoxide hydrolases. These two reactions can be considered to
be detoxications (Sanchez and Kauffman, 2010). 1-Alkenes are metabolised by P450 through both
double bond oxidation to the corresponding epoxide and allylic oxidation (Chiappe et al., 1998). The
rates of the two reactions measured with different P450 isoforms indicate that epoxide formation is
generally favoured (Chiappe et al., 1998).
Based on the low levels of intake of alkenones and alkenols characterised by a carbonyl or an
alcohol group in addition to the terminal double bond, it is expected that the detoxication reactions of
the formed epoxides (conjugation with glutathione or epoxide hydrolase mediated hydrolysis) would
not be saturated and would outweigh the rate of epoxide formation. The presence of the terminal
double bond is therefore not considered of concern under the intended conditions of use.
In addition to reduction and oxidation pathways, low molecular weight alcohols and ketones may
be excreted unchanged in expired air (Brown et al., 1987).
Concluding remarks on metabolism
Fifty-two of the candidate substances, seven saturated aliphatic acyclic secondary alcohols, seven
unsaturated aliphatic secondary alcohols, 12 saturated aliphatic ketones, 10 unsaturated aliphatic
ketones and 16 esters of aliphatic acyclic secondary alcohols and linear and branched-chain aliphatic
carboxylic acids, may be expected to be metabolised to innocuous substances at the estimated levels
of intake, based on the MSDI approach, as ﬂavouring substances.
One candidate substance, 5-methylheptan-3-one [FL-no: 07.182], may be oxidised to a potentially
neurotoxic gamma-diketone. Therefore, this substance will be evaluated via the B-side of the
Procedure (see section 2.4).
More detailed information on the metabolism of candidate substances is given in Appendix D.
2.4. Application of the procedure for the safety evaluation of ﬂavouring
substances
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach.
Where the mTAMDI approach indicates that the intake of a ﬂavouring substance might exceed its
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure.
In these cases, the Panel requires more precise data on use and use levels. For comparison of the
intake estimations based on the MSDI approach and the mTAMDI approach, see Section 2.5.
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For the safety evaluation of the 53 candidate substances the Procedure as outlined in Appendix A
was applied, based on the MSDI approach. The stepwise evaluations of the substances are
summarised in Table B.1.
Step 1
Twenty-eight of the candidate substances [FL-nos: 02.077, 02.124, 02.142, 02.148, 02.177, 02.182,
02.183, 02.190, 02.255, 07.084, 07.178, 07.239, 09.304, 09.323, 09.325, 09.328, 09.332, 09.386,
09.388, 09.391, 09.604, 09.605, 09.606, 09.608, 09.609, 09.676, 09.880 and 09.926] are classiﬁed in
structural class I, according to the decision tree approach presented by Cramer et al. (Cramer et al.,
1978). The remaining 25 candidate substances [FL-nos: 02.131, 02.145, 02.187, 02.194, 02.211,
07.072, 07.150, 07.156, 07.157, 07.158, 07.160, 07.161, 07.162, 07.181, 07.182, 07.185, 07.189,
07.198, 07.199, 07.201, 07.204, 07.205, 07.210, 07.236 and 07.262], which are unsaturated aliphatic
secondary alcohols or acyclic aliphatic saturated or unsaturated ketones, are in structural class II.
Step 2
Fifty-two candidate substances were considered to be metabolised to innocuous products and
would not be expected to saturate available detoxiﬁcation pathways at estimated levels of intake,
based on the MSDI approach, from use as ﬂavouring substances. Therefore, these 52 substances
proceed via the A-side of the Procedure scheme (Appendix A). One candidate substance, 5-
methylheptan-3-one [FL-no: 07.182], cannot be predicted to be metabolised to innocuous products
and therefore, proceeds to step B3.
Step A3
The 28 candidate substances assigned to structural class I, have estimated European daily per
capita intakes ranging from 0.0012 to 1.3 lg (Table 6). These intakes are below the threshold of
concern of 1,800 lg/person per day for structural class I. The 24 unsaturated aliphatic secondary
alcohols and ketones, which have been assigned to structural class II, have estimated European daily
per capita intakes ranging from 0.0012 to 73 lg (Table 6). These intakes are below the threshold of
concern of 540 lg/person per day for structural class II. Based on results of the safety evaluation
sequence, the 52 candidate substances proceeding via the A-side of the Procedure do not pose a
safety concern when used as ﬂavouring substances at the estimated levels of intake, based on the
MSDI approach.
Step B3
The estimated per capita intake of 5-methylheptan-3-one [FL-no: 07.182] of 0.32 lg/capita per day
does not exceed the threshold of concern for structural class II of 540 lg/person per day. Accordingly,
the candidate substance proceeds to step B4 of the Procedure.
Step B4
On the basis of a study on the neurotoxic effects of orally administered 5-methylheptan-3-one [FL-
no: 07.182] to male rats, a no observed adverse effect level (NOAEL) of 82 mg/kg body weight (bw)
per day was established (IBM Corp., 1989). This NOAEL provides a margin of safety of 1.5 9 107
based on the estimated intake of the candidate substance of 0.32 lg/capita per day. Based on results
of the safety evaluation sequence, this candidate substance does not pose a safety concern when used
as ﬂavouring substance at the estimated level of intake, based on the MSDI approach.
2.5. Comparison of the intake estimations based on the MSDI and the
mTAMDI approach
The estimated intakes for the 28 candidate substances in structural class I based on the mTAMDI
approach range from 1,600 to 3,900 lg/person per day. For three [FL-nos: 07.084, 07.178 and 07.239]
of these 28 substances, the mTAMDI is below the threshold of concern of 1,800 lg/person per day.
The estimated intake for the 21 candidate substances assigned to structural class II based on the
mTAMDI range from 1,500 to 6,600 lg/person per day, which are all above the threshold of concern
for structural class II substances of 540 lg/person per day.
Therefore, for 50 candidate substances, further information is required. This would include more
reliable intake data and then, if required, additional toxicological data.
For comparison of the MSDI and mTAMDI values, see Table 6.
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Table 6: Estimated intakes based on the MSDI approach and the mTAMDI approach












02.077 Pentan-3-ol 0.19 3,900 Class I 1,800
02.124 6-Methylhept-5-en-2-ol 0.0061 3,900 Class I 1,800
02.142 3,3-Dimethylbutan-2-ol 0.24 3,900 Class I 1,800
02.148 Dodecan-2-ol 0.35 3,900 Class I 1,800
02.177 2-Methylhexan-3-ol 0.12 3,900 Class I 1,800
02.182 3-Methylpentan-2-ol 0.12 3,900 Class I 1,800
02.183 4-Methylpentan-2-ol 0.0012 3,900 Class I 1,800
02.190 Nonan-3-ol 0.011 3,900 Class I 1,800
02.255 (Z)-4-Hepten-2-ol 0.03 2,500 Class I 1,800
07.084 Pentan-3-one 0.24 1,600 Class I 1,800
07.178 3-Methylbutan-2-one 0.073 1,600 Class I 1,800
07.239 [R-(E)]-5-Isopropyl-8-
methylnona-6,8-dien-2-one
0.24 1,600 Class I 1,800
09.304 sec-Heptyl isovalerate 0.0012 3,900 Class I 1,800
09.323 sec-Butyl acetate 0.0012 3,900 Class I 1,800
09.325 sec-Butyl butyrate 1.3 3,900 Class I 1,800
09.328 sec-Butyl formate 0.12 3,900 Class I 1,800
09.332 sec-Butyl hexanoate 0.024 3,900 Class I 1,800
09.386 sec-Hept-4(cis)-enyl acetate 0.024 3,900 Class I 1,800
09.388 sec-Heptyl acetate 0.12 3,900 Class I 1,800
09.391 sec-Heptyl hexanoate 0.12 3,900 Class I 1,800
09.604 Isopropyl decanoate 0.12 3,900 Class I 1,800
09.605 Isopropyl dodecanoate 0.12 3,900 Class I 1,800
09.606 Isopropyl hexadecanoate 0.012 3,900 Class I 1,800
09.608 Isopropyl octanoate 1.3 3,900 Class I 1,800
09.609 Isopropyl valerate 0.012 3,500 Class I 1,800
09.676 sec-Octyl acetate 0.011 3,900 Class I 1,800
09.880 (Z)-Hept-4-enyl-2 butyrate 0.79 3,900 Class I 1,800
09.926 Octan-3-yl formate 0.24 3,900 Class I 1,800
02.131 But-3-en-2-ol 0.0012 3,900 Class II 540
02.145 2,6-Dimethylocta-1,5,7-
trien-3-ol
0.0085 3,900 Class II 540
02.187 Non-1-en-3-ol 0.58 3,900 Class II 540
02.194 Octa-1,5-dien-3-ol 0.061 3,900 Class II 540
02.211 Undeca-1,5-dien-3-ol 0.061 3,900 Class II 540
07.072 6-Methylheptan-3-one 0.19 1,600 Class II 540
07.150 Decan-2-one 0.52 1,600 Class II 540
07.156 2,6-Dimethyloct-6-en-3-one
(mixture of E and Z)
0.0012 1,600 Class II 540
07.157 6,10-Dimethylundecan-2-
one
0.085 1,500 Class II 540
07.158 Dodecan-2-one 0.73 1,600 Class II 540
07.160 Heptadecan-2-one 0.12 1,600 Class II 540
07.161 Hex-1-en-3-one 0.012 1,600 Class II 540
07.162 Hex-5-en-2-one 0.049 1,600 Class II 540
07.181 6-Methylheptan-2-one 0.0012 1,600 Class II 540
07.182 5-Methylheptan-3-one 0.32 1,600 Class II 540
07.185 3-Methylpentan-2-one 1.2 1,600 Class II 540
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2.6. Considerations of combined intakes from use as ﬂavouring
substances
Because of structural similarities of candidate and supporting substances, it can be anticipated that
many of the ﬂavourings are metabolised through the same metabolic pathways and that the
metabolites may affect the same target organs. Furthermore, in case of combined exposure to
structurally related ﬂavourings, the pathways could be overloaded. Therefore, combined intake should
be considered. As ﬂavourings not included in this FGE may also be metabolised through the same
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed.
The total estimated combined daily per capita intake of structurally related ﬂavourings is estimated by
summing the MSDI for individual substances.
On the basis of the reported annual production volumes in Europe (EFFA, 2002b, c, 2007c; Flavour
Industry, 2009), the total estimated daily per capita intake as ﬂavourings of the 28 candidate ﬂavouring
substances assigned to structural class I is 6 lg, which does not exceed the threshold of concern for a
substance belonging to structural class I of 1,800 lg/person per day. For the combined intake of the 25
candidate ﬂavouring substances assigned to structural class II is 78 lg, which does not exceed the
threshold of concern for a substance belonging to structural class II of 540 lg/person per day.
The 53 candidate substances are structurally related to 67 supporting substances evaluated by the
JEFCA at its 51st, 59th and 69th meetings in the groups ‘Saturated aliphatic acyclic secondary alcohols,
ketones, and related saturated and unsaturated esters’ (JECFA, 2000a, 2002a, 2003, 2009b). The total
combined intake of candidate and supporting substances of structural class I and II would be
90,450 lg/capita per day and 1,430 lg/capita per day, respectively. Both intakes exceed the threshold
of their structural class of 1,800 and 540 lg/person per day. However, the major contribution (> 99%)
was provided by two supporting substances, namely acetone [FL-no: 07.050] (6,100 lg/capita per
day) and isopropanol [FL-no: 02.079] (84,000 lg/capita per day). These are present in the body as
endogenous compounds, which are easily eliminated, either by excretion into the urine and exhaled air
or after enzymatic metabolism (Morgott, 1993). Therefore, they would not be expected to give rise to
perturbations outside the physiological range (JECFA, 1999a). Excluding the two major contributors,
the estimated total combined intake (in Europe) for the candidate (Table 6) and supporting substances
(Table B.3) belonging to structural class I would be 350 lg/capita per day, which does not exceed the
threshold of concern for the corresponding structural class (1,800 lg person per day); the estimated
total combined intake (in Europe) for the candidate (Table 6) and supporting substances (Table B.3)
belonging to structural class II would be 1,430 lg/capita per day, which is 2.6 fold higher than the
threshold of concern for the corresponding structural class (540 lg/person per day). Five of the
supporting substances from structural class II, oct-1-en-3-ol, heptan-2-one, undecan-2-one, nonan-2-
one and tridecan-2-one [FL-nos: 02.023, 07.002, 07.016, 07.020 and 07.103], contribute with 1,050
lg/capita per day to the combined MSDI of 1,430 lg/capita per day (Table B.3). A 90-day study for












07.189 Nonan-4-one 0.52 1,600 Class II 540
07.198 Pseudo-ionone 0.12 1,600 Class II 540
07.199 Tetradecan-2-one 0.073 1,600 Class II 540
07.201 Tridec-12-en-2-one 0.024 1,600 Class II 540
07.204 3,3,6-Trimethylhepta-1,5-
dien-4-one
0.012 1,600 Class II 540
07.210 1-Nonene-3-one 0.0012 1,600 Class II 540
07.205 6,10,14-
Trimethylpentadecan-2-one
0.0073 1,500 Class II 540
07.236 (Z)-5-Octen-2-one 0.0097 1,600 Class II 540
07.262 9-Decen-2-one 73 6,600 Class II 540
MSDI: Maximised Survey-derived Daily Intake; mTAMDI: modiﬁed Theoretical Added Maximum Daily Intake; TTC: toxicological
threshold of concern.
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nonan-2-one [FL-no: 07.020] (O’Donoghue and Krasavage, 1980) provides a NOAEL of 2,000 mg/kg
bw per day. Based on this NOAEL, a margin of safety of 11.5 9 104 can be derived for the combined
intake of [FL-nos: 02.023, 07.002, 07.016, 07.020 and 07.103]. For the remaining substances from
structural class II, the estimated combined intake of 380 lg/capita per day is below the threshold of
structural class II of 540 lg/capita per day.
If the candidate substance 5-methylheptan-3-one [FL-no: 07.182] and the two supporting
substances heptan-3-ol [FL-no: 02.044] and 3-heptanone [FL-no: 07.003], which can all be
metabolised to neurotoxic gamma-diketones, were consumed concomitantly on a daily basis, the
estimated combined intake (in Europe) would be 3.7 lg/capita per day, corresponding to 0.06 lg/kg
bw per day. This value does not exceed the threshold of concern for the corresponding structural class
II (540 lg/person per day) and is also much lower than the NOAEL for 5-methylheptan-3-one [FL-no:
07.182] of 82 mg/kg bw per day for neurotoxicity in the rat. Therefore, it can be concluded that there
is no safety concern for human health for the combined exposure to these three neurotoxic substances
at the estimated level of intake as ﬂavourings.
2.7. Genotoxicity
In vitro
In vitro genotoxicity data have been reported for nine candidate substances. Negative results were
obtained in bacterial systems (+/ metabolic activation) with six candidate substances, one saturated
aliphatic acyclic secondary alcohol [FL-no: 02.183], two saturated ketones [FL-nos: 07.181 and
07.205], two unsaturated ketones [FL-nos: 07.198 and 07.262] and the ester isopropyl hexadecanoate
[FL-no: 09.606]. Negative results were also obtained for the candidate substances pseudo-ionone [FL-
no: 07.198], pentan-3-ol [FL-no: 02.077] and methyl-3-butan-2-one [FL-no: 07.178], the two-ﬁrst
mentioned being tested for chromosomal aberrations in mammalian cells and the latter for induction of
aneuploidy in yeast cells, respectively.
Induction of aneuploidy in yeast cells has been demonstrated for pentan-3-one [FL-no: 07.084].
The effect, measured only at high concentrations, approaching cytotoxic levels, can be considered to
be a threshold effect, not mediated by direct interaction with DNA. In addition, induction of aneuploidy
described in the paper is strongly potentiated by ice treatments included in the experimental protocol,
consistently with tubulin dissociation at low temperature in vitro; in the absence of this passage the
effect is very weak. Therefore, the effect could be considered as an effect occurring only under
unrealistic experimental conditions and the extrapolation of this result to the in vivo situation in
humans is questionable. Furthermore, it is well recognised that the relevance of fungal systems is
limited when induction of aneuploidy in mammalian systems has to be evaluated.
Pseudo-ionone [FL-no: 07.198] was considered with respect to genotoxicity in FGE.206 (EFSA CEF
Panel, 2011) where the Panel concluded that the data available ruled out the concern for genotoxicity.
Pseudo-ionone was tested in Salmonella Typhimurium strains TA98, TA100, TA1535, TA1537 and TA102
in the presence or absence of S9 and it is concluded that under the test conditions applied pseudo-
ionone is not mutagenic in bacteria. Pseudo-ionone was also evaluated in an in vitro micronucleus assay
in human peripheral blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in
the presence and absence of rat S9 fraction as an in vitro metabolising system. Under the conditions of
this study, pseudo-ionone was not clastogenic and/or aneugenic in cultured human lymphocytes. As
pseudo-ionone [FL-no: 07.198] is a representative with respect to genotoxicity evaluation for [FL-nos:
02.145, 02.194, 02.211 and 07.204] in FGE.206 the safety concern for genotoxicity can also be ruled
out for these four substances and they can be evaluated using the Procedure in the present FGE.
In vitro genotoxicity data are also available for 10 supporting substances.
No evidence of mutagenicity obtained with either bacterial or mammalian cells systems was
reported for one saturated aliphatic acyclic secondary alcohol [FL-no: 02.079], ﬁve saturated [FL-nos:
07.002, 07.050, 07.017, 07.053 and 07.122], two unsaturated [FL-nos: 07.015 and 07.099] aliphatic
acyclic ketones and two esters of an aliphatic acyclic secondary alcohol with linear aliphatic carboxylic
acids [FL-nos: 09.003 and 09.105]. 4-Methyl-2-pentanone [FL-no: 07.017] gave negative results also
when tested for chromosomal aberration activity.
Besides the negative results in in vitro bacterial point mutation tests, acetone [FL-no: 07.050]
showed no evidence of increased sister chromatid exchanges in several cytogenetic assays on different
mammalian cells, as well as no induction of chromosomal aberrations in Chinese hamster ovary cells
up to very high concentrations. Only one test on hamster lung ﬁbroblasts (conducted at an unspeciﬁed
Flavouring Group Evaluation 07 Revision 5
www.efsa.europa.eu/efsajournal 20 EFSA Journal 2017;15(3):4725
acetone concentration) and an aneuploidy induction test on Saccharomyces cerevisiae (about 7%
acetone) gave positive results. However, these two studies were considered not relevant on the basis
of their poor quality and taking into account all the other negative genotoxicity results obtained with
acetone, including results in vivo (see below).
6-Methylhepta-3,5-dien-2-one [FL-no: 07.099] was considered with respect to genotoxicity in
FGE.206 (EFSA CEF Panel, 2011) where the Panel concluded that the data available ruled out the
concern for genotoxicity. 6-Methylhepta-3,5-dien-2-one was tested in S. Typhimurium strains TA98,
TA100, TA1535, TA1537 and TA102 in the presence or absence of S9 and it was concluded that under
the test conditions applied 6-methylhepta-3,5-dien-2-one is not mutagenic in bacteria. 6-Methylhepta-
3,5-dien-2-one was also evaluated in an in vitro micronucleus assay in human peripheral blood
lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and absence of
rat S9 fraction as an in vitro metabolising system. Under the conditions of this study, 6-methylhepta-3,
5-dien-2-one was not clastogenic and/or aneugenic in cultured human lymphocytes. As 6-methylhepta-
3,5-dien-2-one [FL-no: 07.099] is a representative with respect to genotoxicity evaluation for [FL-nos:
02.145, 02.194, 02.211 and 07.204] in FGE.206, the safety concern for genotoxicity can also be ruled
out for these four substances and they can be evaluated using the Procedure in the present FGE.
In vivo
In vivo data are available for four supporting substances: one saturated aliphatic secondary alcohol
[FL-no: 02.079] and three saturated aliphatic ketones [FL-nos: 07.017, 07.050 and 07.053], which
exhibited no genotoxic potential in the micronucleus cytogenetic assay at doses approaching the LD20
and the LD50 of the tested substances.
Candidate substances with alpha-beta-unsaturated carbonyl structural alert
Oct-1-en-3-one [FL-no: 07.081] and pent-1-en-3-one [FL-no: 07.102] were evaluated with respect
to genotoxicity in FGE.205 (EFSA CEF Panel, 2012a) and FGE.205Rev1 (EFSA CEF Panel, 2016). Due to
positive effects in the bacterial mutagenicity assays of the two representative substances pent-1-en-3-
one [FL-no: 07.102] and oct-1-en-3-one [FL-no: 07.081], an in vivo Comet assay on the ﬁrst site of
contact (e.g. the stomach or duodenum) and on the liver was requested on the most potent
substance, pent-1-en-3-one (EFSA CEF Panel, 2012a). In response to the data request in FGE.205, the
industry submitted in vivo data on both pent-1-en-3-one and oct-1-en-3-one. Pent-1-en-3-one [FL-no:
07.102] was tested for its potential to induce micronuclei in the polychromatic erythrocytes of the bone
marrow of treated rats and to induce DNA damage in the liver and duodenum of the same animals
(Keig-Shevlin, 2015b,c). Oct-1-en-3-one [FL-no: 07.081] was tested in a Comet assay for its potential
to induce DNA damage in the liver of rats (Keig-Shevlin, 2015a). Furthermore, to investigate the
mechanism of action of the mutagenic activity observed in the bacterial reverse mutation tests of
previous studies, a new Ames test with oct-1-en-3-one was performed with strain TA100 (Bowen,
2013). Pent-1-en-3-one [FL-no: 07.102] tested in vivo in a combined micronucleus and comet assay
did not show genotoxic effects in either the liver or duodenum of treated rats. The negative results of
the bone marrow micronucleus assay are considered inconclusive because there is no evidence of
bone marrow exposure to the tested substance. However, as results of the in vitro micronucleus assay
were negative, no additional in vivo follow-up studies on clastogenicity and aneugenicity were needed.
The bacterial mutation assay provided for oct-1-en-3-one [FL-no: 07.081] conﬁrms the weak
mutagenic effect in bacteria shown in previous studies, but does not clarify the mechanism of action.
The liver comet assay is considered of limited validity due to low values of mean tail intensity and tail
moment. However, based on the data available on the most potent of the two representative
substances for the other substances of FGE.205, pent-1-en-3-one [FL-no: 07.102], the Panel concluded
that there is no concern for genotoxicity. As pent-1-en-3-one [FL-no: 07.102] is a representative with
respect to genotoxicity evaluation for [FL-nos: 02.131, 02.187, 07.161 and 07.210] in FGE.205, the
safety concern for genotoxicity can also be ruled out for these four substances and they will be
evaluated using the Procedure in the present FGE.
Overall conclusion on genotoxicity
From the available in vitro and in vivo tests on candidate and supporting substances and on the
basis of the results for substances evaluated in FGE.205, FGE.206 and FGE.205rev1 (EFSA CEF Panel,
2011, 2012a, 2016), no concern is raised with respect to genotoxicity. Consequently the candidate
substances can be evaluated using the Procedure.
The genotoxicity data are summarised in Appendix E, Tables E.4–E.7.
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2.8. Toxicity
2.8.1. Acute toxicity
Data are available for 12 candidate substances under consideration and for 23 supporting
substances. Most of the candidate and supporting substances have rat and/or mouse oral LD50 values
exceeding 2,000 mg/kg bw indicating that their oral acute toxicity is low.
The acute toxicity data are summarised in Appendix E, Table E.1.
2.8.2. Short-term and subchronic toxicity
Data on oral subchronic toxicity are available for three candidate substances, pentan-3-one [FL-no:
07.084], 5-methylheptan-3-one [FL-no: 07.182] and 9-decen-2-one [FL-no: 07.262] with identiﬁcation
of a NOAEL. Data on subacute and subchronic oral toxicity are also available for ten supporting
substances, one saturated aliphatic secondary alcohol [FL-no: 02.079], seven saturated [FL-nos:
07.002, 07.003, 07.017, 07.020, 07.050, 07.058, 07.122] and two unsaturated [FL-nos: 07.100 and
07.114] aliphatic ketones evaluated by JEFCA (JECFA, 1999a, 2003).
During the application of the Procedure (Appendix A), the following study on 5-methylheptan-3-one
[FL-no: 07.182], which possesses structural alerts for neurotoxicity, has been used to calculate the
NOAEL: 5-Methylheptan-3-one [FL-no: 07.182] (purity 98.9%) dissolved in distilled water was
administered by gavage to groups of ﬁve adult male Sprague–Dawley rats at dose levels 0, 82, 410
and 820 mg/kg bw per day, ﬁve days/week for 13 weeks. In the high-dose group, clinical signs,
including depression of activity, gait disturbances, reductions in food consumption and body weight
gain were observed; moreover, results of the Functional Observational Battery (FOB) indicated
peripheral neuropathy. Similar clinical signs and functional deﬁcits were observed less frequently and
with reduced severity in the mid-dose group. No functional deﬁcits were observed in the low-dose
group animals. Microscopic histopathological examinations of the sciatic and tibial nerves from high-
dose animals revealed lesions typical of the ‘giant’ axonal neuropathy produced by gamma-diketones.
Changes observed in the mid-dose group animals reﬂected the occurrence of reparative processes in
the nerves. Nerves from the low-dose group animals did not show any evidence of pathology
attributable to treatment. Based on behavioural effects and microscopic changes occurring at 410 and
820 mg/kg bw per day, the NOAEL for 5- methylheptan-3-one induced neurotoxicity was 82 mg/kg bw
per day (IBM Corp., 1989).
The short-term and subchronic toxicity data are summarised in Appendix E, Table E.2.
2.8.3. Reproductive and developmental toxicity
Data on reproductive toxicity are available for pentan-3-one [FL-no: 07.084] and data on
developmental toxicity are available for pseudo-ionone [FL-no: 07.198]. For one supporting substance,
isopropyl alcohol [FL-no: 02.079], data are available on both developmental and reproductive toxicity.
With a NOAEL of 50 mg/kg bw per day for intraperitoneal administration in mice for [FL-no: 07.084]
and of 960 mg/kg bw per day for oral administration of [FL-no: 07.198], it was concluded that the
developmental/reproductive toxicity was low after oral exposure.
The developmental/reproductive toxicity data are summarised in Appendix E, Table E.3.
2.8.4. Other studies
Pseudo-ionone [FL-no: 07.198] has been subjected to investigations concerning its potential as a
dermal sensitiser as follows:
a) A guinea pig study (Csato and Chubb, 1996) performed as a GLP OECD 406 maximisation
test. There were some problems with reading the result after challenge because of intense
red-brown skin staining. Therefore a rechallenge was performed 7 days later, when skin
staining was much reduced and did not prevent assessment of the skin reaction. Test agent
concentrations were 3.125% and 1.563% in water, scoring was performed after 24 and 48 h.
None of the animals in the control (n = 10) or test (n = 20) groups showed a reaction. Based
on this guinea pig maximisation test performed under GLP conditions according to OECD
guidelines, pseudo-ionone is not a dermal sensitiser. However, the problems with skin staining
and delayed challenge possibly may bring in some uncertainty (contribution toward false
negative results).
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b) Four maximisation test series with pseudo-ionone were carried out on a total of 108 human
volunteers by Kligman (1976) [unpublished] and Epstein (1978) [unpublished]. Test
concentration was 8% in petrolatum. The outcome was ‘2/25 (Kligman, 1976), 4/25 (Epstein,
1978), 2/25 (Kligman, 1976), and 1/33 (Epstein, 1978) sensitisation reactions’, as reported by
Ford et al. (1988). Thus, there were altogether nine positive out of 108 subjects (8.3%). No
further details are given by Ford and the original reports never were published. The fact that
pseudo-ionone is an irritant still may bring in some uncertainty (contribution towards false
positive results).
Based on the human studies, there is evidence that pseudo-ionone may be a weak dermal sensitiser.
In accordance with this and as based on the report by Ford et al. (Ford et al., 1988), both the
International Fragrance Association (IFRA, 2002) and subsequently the European Union Scientiﬁc
Committee on Cosmetic Products and Non-Food Products (SCCNFP, 2000) recommended a ban on the
use of pseudo-ionone as a fragrance ingredient but tolerated it as an impurity at ≤ 2% in various ionones.
Considering that allergic contact sensitisation in the mouth to components in ingested food is
extremely rare (EFSA CEF Panel, 2012b), that worsening of skin manifestations of contact dermatitis after
ingestion of foods with relatively high levels of the allergen appears to be an uncommon occurrence, and
that contact allergic manifestations in the gut although claimed in rare cases have not been well
described, it is unlikely that pseudo-ionone used as a ﬂavouring substance will cause allergic reactions.
3. Conclusions
Following a request from the European Commission, the EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (CEF) was asked to deliver a scientiﬁc opinion on the
implications for human health of chemically deﬁned ﬂavouring substances used in or on foodstuffs in
the Member States. In particular, the Panel was requested to evaluate 53 ﬂavouring substances
allocated to the FGE.07Rev5, using the Procedure as referred to in the Commission Regulation (EC)
No 1565/20003. These ﬂavouring substances are listed in the Union List, which was adopted by
Commission Regulation (EU) No 872/20122 and its consecutive amendments.
The present Revision of FGE.07, FGE.07Rev5, includes the assessment of four additional candidate
substances [FL-nos: 02.131, 02.187, 07.161 and 07.210]. These substances possess an a,b-unsaturated
structure, which is considered a structural alert for genotoxicity. They have been evaluated by EFSA in
FGE.205Rev1, and the genotoxicity concern could be ruled out. The Panel concluded that the
substances with [FL-nos: 02.131, 02.187, 07.161 and 07.210] can be evaluated through the Procedure.
The 53 candidate substances are saturated and unsaturated aliphatic secondary alcohols, ketones
and esters of secondary alcohols and saturated linear or branched-chain saturated carboxylic acids
from chemical group 5.
Twenty-seven candidate substances possess one chiral centre [FL-nos: 02.124, 02.131, 02.142,
02.145, 02.148, 02.177, 02.183, 02.187, 02.190, 02.194, 02.211, 02.255, 07.157, 07.182, 07.185,
07.239, 09.304, 09.323, 09.325, 09.328, 09.332, 09.386, 09.388, 09.391, 09.676, 09.880 and 09.926],
and two of the candidate substances possess two chiral centres [FL-nos: 02.182 and 07.205].
Due to the presence and the position of double bonds, 10 candidate substances can exist as
geometrical isomers [FL-nos: 02.145, 02.194, 02.211, 02.255, 07.156, 07.198, 07.236, 07.239, 09.386,
and 09.880].
Twenty-eight candidate substances belong to structural class I, and 25 candidate substances belong
to structural class II.
Forty-ﬁve of the ﬂavouring substances in the present group of 53 ﬂavouring substances have been
reported to occur naturally in a wide range of food items.
According to the default MSDI approach, 53 candidate substances have European daily per capita
intakes ranging from 0.0012 to 73 lg, which are below the threshold of concern for structural class I
and class II substances (1,800 and 540 lg/person per day, respectively). On the basis of the reported
annual production in Europe (MSDI approach), the combined intakes of the 28 of the candidate
substances belonging to structural class I and of the 25 candidate substances belonging to structural
class II would result in total intakes of 6 and 78 lg/capita per day, respectively.
These values are lower than the thresholds of concern for structural class I or class II substances.
The total combined estimated levels of intake of the candidate and supporting substances is
approximately 350 lg/capita per day (without acetone and isopropanol) for structural class I
substances and 1,430 lg/capita per day for structural class II substances. This latter value does
exceed the threshold of concern for the structural class. For the structural class II substances, ca 70%
Flavouring Group Evaluation 07 Revision 5
www.efsa.europa.eu/efsajournal 23 EFSA Journal 2017;15(3):4725
of the combined exposure estimate is represented by ﬁve supporting substances [FL-nos: 02.023,
07.002, 07.016, 07.020 and 07.103]. For [FL no: 07.020], a NOAEL of 2,000 mg/kg bw per day has
been reported, which provides an adequate margin of safety of 11.5 9 104. For the remaining 20
structural class II substances, the combined exposure estimate (380 lg/capita per day) remains below
the TTC for this structural class.
From the available in vitro and in vivo tests on candidate and supporting substances, no concern is
raised with respect to genotoxicity. Fifty-two candidate substances would be expected to be
metabolised to innocuous substances at the estimated levels of intake as ﬂavouring substances. One
candidate substance, 5-methylheptan-3-one [FL-no: 07.182], may be oxidised to a potential neurotoxic
gamma-diketone. However, this metabolic path does not pose a safety concern at the estimated level
of intake as a ﬂavouring substance. Indeed, for this substance, a NOAEL for neurotoxicity of 82 mg/kg
bw per day was established in a subchronic study on adult male rats dosed with 0, 82, 410 and
820 mg/kg bw per day for 13 weeks. This NOAEL provides a margin of safety of 1.5 9 107 based on
the estimated intake (MSDI) of the candidate substance of 0.32 lg/capita per day.
Otherwise, it was noted that where toxicity data were available on single ﬂavouring substances
they were consistent with the conclusions in the present FGE using the Procedure.
It is considered that on the basis of the default MSDI approach none of the 53 candidate
substances would give rise to safety concerns at the estimated levels of intake arising from their use
as ﬂavouring substances.
In order to determine whether the conclusion for the 53 candidate substances evaluated through
the Procedure can be applied to the materials of commerce, it is necessary to consider the available
speciﬁcations. Adequate speciﬁcations including purity and identity for the materials of commerce have
been provided for all the candidate substances.
The Panel concluded that all 53 ﬂavouring substances [FL-nos: 02.077, 02.124, 02.131, 02.142,
02.145, 02.148, 02.177, 02.182, 02.183, 02.187, 02.190, 02.194, 02.211, 02.255, 07.072, 07.084,
07.150, 07.156, 07.157, 07.158, 07.160, 07.161, 07.162, 07.178, 07.181, 07.182, 07.185, 07.189,
07.198, 07.199, 07.201, 07.204, 07.205, 07.210, 07.236, 07.239, 07.262, 09.304, 09.323, 09.325,
09.328, 09.332, 09.386, 09.388, 09.391, 09.604, 09.605, 09.606, 09.608, 09.609, 09.676, 09.880 and
09.926] evaluated in this FGE would not be expected to present a safety concern at their estimated
levels of intake based on the MSDI approach.
When the estimated intakes were based on the mTAMDI, they ranged from 1,600 to
3,900 lg/person per day for the 28 candidate substances from structural class I. The intakes were all
above the threshold of concern for structural class I of 1,800 lg/person per day, except for three
ﬂavouring substances [FL-nos: 07.084, 07.178 and 07.239]. These three substances have mTAMDI
intake estimates below the threshold of concern for the structural class, and are also expected to be
metabolised to innocuous products. The estimated intakes of the 25 candidate substances assigned to
structural class II, based on the mTAMDI, range from 1,500 to 6,600 lg/person per day, which are all
above the threshold of concern for structural class II of 540 lg/person per day.
In conclusion, for all candidate substances except [FL-nos: 07.084, 07.178 and 07.239] further
information is required. This would include more reliable intake data and then, if required, additional
toxicological data.
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CoE Council of Europe
EFFA European Flavour and Fragrance Association
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
FOB Functional Observational Battery
HGPRT hypoxanthine-guanine phosphoribosyltransferase
ID identity
IFRA International Fragrance Association
IOFI International Organization of the Flavour Industry
IP intraperitoneal
IR infrared spectroscopy
JECFA The Joint FAO/WHO Expert Committee on Food Additives
LD50 lethal dose, 50%; Median lethal dose
MS mass spectrometry
MSDI Maximised Survey-derived Daily Intake
mTAMDI Modiﬁed Theoretical Added Maximum Daily Intake
NAD nicotinamide adenine dinucleotide
NADH nicotinamide adenine dinucleotide – reduced form
NADP nicotinamide adenine dinucleotide phosphate
NADPH nicotinamide adenine dinucleotide phosphate – reduced form
NOAEL no observed adverse effect level
NMR nuclear magnetic resonance
NTP National Toxicology Program
SCCNFP European Union Scientiﬁc Committee on Cosmetic Products and Non-Food Products
SCE sister chromatid exchange
SCF Scientiﬁc Committee on Food
TAMDI Theoretical Added Maximum Daily Intake
TTC toxicological threshold of concern
UGAC average urinary output of glucuronide
VCF Volatile Compounds in Food
WHO World Health Organisation
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Appendix A – Procedure for the safety evaluation
The approach for a safety evaluation of chemically deﬁned ﬂavouring substances as referred to in
Commission Regulation (EC) No 1565/20003, named the ‘Procedure’, is shown in schematic form in
Figure A.1. The Procedure is based on the Opinion of the Scientiﬁc Committee on Food expressed on 2
December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995,
1996, 1997, 1999b).
The Procedure is a stepwise approach that integrates information on intake from current uses,
structure–activity relationships, metabolism and, when needed, toxicity. One of the key elements in the
Procedure is the subdivision of ﬂavourings into three structural classes (I, II and III) for which
thresholds of concern (human exposure thresholds) have been speciﬁed. Exposures below these
thresholds are not considered to present a safety concern.
Class I contains ﬂavourings that have simple chemical structures and efﬁcient modes of
metabolism, which would suggest a low order of oral toxicity. Class II contains ﬂavourings that have
structural features that are less innocuous, but are not suggestive of toxicity. Class III comprises
ﬂavourings that have structural features that permit no strong initial presumption of safety, or may
even suggest signiﬁcant toxicity (Cramer et al., 1978). The thresholds of concern for these structural
classes of 1,800, 540 or 90 lg/person per day, respectively, are derived from a large database
containing data on subchronic and chronic animal studies (JECFA, 1996).
In Step 1 of the Procedure, the ﬂavourings are assigned to one of the structural classes. The
further steps address the following questions:
• Can the ﬂavourings be predicted to be metabolised to innocuous products8 (Step 2)?
• Do their exposures exceed the threshold of concern for the structural class (Steps A3 and B3)?
• Are the ﬂavourings or their metabolites endogenous9 (Step A4)?
• Does a NOAEL exist on the ﬂavourings or on structurally related substances (Steps A5 and B4)?
In addition to the data provided for the ﬂavouring substances to be evaluated (candidate
substances), toxicological background information available for compounds structurally related to the
candidate substances is considered (supporting substances), in order to assure that these data are
consistent with the results obtained after application of the Procedure.
The Procedure is not to be applied to ﬂavourings with existing unresolved problems of toxicity.
Therefore, the right is reserved to use alternative approaches if data on speciﬁc ﬂavourings warranted
such actions.
8 ‘Innocuous metabolic products’: Products that are known or readily predicted to be harmless to humans at the estimated
intakes of the ﬂavouring agent (JECFA, 1997).
9 ‘Endogenous substances’: Intermediary metabolites normally present in human tissues and ﬂuids, whether free or conjugated;
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997).
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Appendix C – Use levels/mTAMDI
Normal and maximum use levels
For each of the 18 food categories (Table C.1) in which the candidate substances are used, ﬂavour
industry reports a ‘normal use level’ and a ‘maximum use level’.1 According to the ﬂavour industry, the
‘normal use’ is deﬁned as the average of reported usages and ‘maximum use’ is deﬁned as the 95th
percentile of reported usages (EFFA, 2002d). The normal and maximum use levels in different food
categories have been extrapolated from ﬁgures derived from 12 model ﬂavouring substances
(EFFA, 2004).
The ‘normal and maximum use levels’ are provided by industry for all 49 candidate substances in
the present ﬂavouring group (Table C.3).
mTAMDI calculations
The method for calculation of modiﬁed Theoretical Added Maximum Daily Intake (mTAMDI) values is
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may
consume the amount of ﬂavourable foods and beverages listed in Table C.2. These consumption
estimates are then multiplied by the reported use levels in the different food categories and summed up.
Table C.1: Food categories according to Commission Regulation (EC) No 1565/20003
Food category Description
01.0 Dairy products, excluding products of category 02.0
02.0 Fats and oils, and fat emulsions (type water-in-oil)
03.0 Edible ices, including sherbet and sorbet
04.1 Processed fruit
04.2 Processed vegetables (including mushrooms & fungi, roots & tubers,
pulses and legumes), and nuts & seeds
05.0 Confectionery
06.0 Cereals and cereal products, including ﬂours & starches from roots & tubers,
pulses & legumes, excluding bakery
07.0 Bakery wares
08.0 Meat and meat products, including poultry and game
09.0 Fish and ﬁsh products, including molluscs, crustaceans and echinoderms
10.0 Eggs and egg products
11.0 Sweeteners, including honey
12.0 Salts, spices, soups, sauces, salads, protein products, etc.
13.0 Foodstuffs intended for particular nutritional uses
14.1 Non-alcoholic (‘soft’) beverages, excl. dairy products
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts
15.0 Ready-to-eat savouries
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not
be placed in categories 01.0–15.0
Table C.2: Estimated amount of ﬂavourable foods, beverages, and exceptions assumed to be
consumed per person per day (SCF, 1995)
Class of product category Intake estimate (g/day)
Beverages (non-alcoholic) 324.0
Foods 133.4
Exception a: Candy, confectionery 27.0
Exception b: Condiments, seasonings 20.0
Exception c: Alcoholic beverages 20.0
Exception d: Soups, savouries 20.0
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum)
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The mTAMDI calculations are based on the normal use levels reported by industry. The seven food
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as
outlined in Commission Regulation (EC) No 1565/20003 and reported by the ﬂavour industry in the
following way (see Table C.3):
• Beverages (SCF, 1995) correspond to food category 14.1
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or
16
• Exception a (SCF, 1995) corresponds to food category 5 and 113
• Exception b (SCF, 1995) corresponds to food category 153
• Exception c (SCF, 1995) corresponds to food category 14.23
• Exception d (SCF, 1995) corresponds to food category 123
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum.
Table C.3: Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/20003
into the seven SCF food categories used for TAMDI calculation (SCF, 1995)
Food categories according to Commission Regulation
(EC) No 1565/20003
Distribution of the seven SCF food
categories
Key Food category Food Beverages Exceptions
01.0 Dairy products, excluding products of category 02.0 Food
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food
03.0 Edible ices, including sherbet and sorbet Food
04.1 Processed fruit Food
04.2 Processed vegetables (including mushrooms & fungi, roots &
tubers, pulses and legumes), and nuts & seeds
Food
05.0 Confectionery Exception a
06.0 Cereals and cereal products, including ﬂours & starches from
roots & tubers, pulses & legumes, excluding bakery
Food
07.0 Bakery wares Food
08.0 Meat and meat products, including poultry and game Food
09.0 Fish and ﬁsh products, including molluscs, crustaceans and
echinoderms
Food
10.0 Eggs and egg products Food
11.0 Sweeteners, including honey Exception a
12.0 Salts, spices, soups, sauces, salads, protein products, etc. Exception d
13.0 Foodstuffs intended for particular nutritional uses Food
14.1 Non-alcoholic (‘soft’) beverages, excl. dairy products Beverages
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic
counterparts
Exception c
15.0 Ready-to-eat savouries Exception b
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) -
foods that could not be placed in categories 01.0–15.0
Food
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The mTAMDI values (see Table C.5) are presented for each of the 49 ﬂavouring substances in the
present ﬂavouring group, for which industry has provided use and use levels (EFFA, 2002a,c, 2007a,b,
c; Flavour Industry, 2006, 2009). The mTAMDI values are only given for highest reported normal use
levels (see Table C.4).
Table C.5: Estimated intakes based on the mTAMDI approach










02.077 Pentan-3-ol 3,900 Class I 1,800
02.124 6-Methylhept-5-en-2-ol 3,900 Class I 1,800
02.142 3,3-Dimethylbutan-2-ol 3,900 Class I 1,800
02.148 Dodecan-2-ol 3,900 Class I 1,800
02.177 2-Methylhexan-3-ol 3,900 Class I 1,800
02.182 3-Methylpentan-2-ol 3,900 Class I 1,800
02.183 4-Methylpentan-2-ol 3,900 Class I 1,800
02.190 Nonan-3-ol 3,900 Class I 1,800
02.255 (Z)-4-Hepten-2-ol 2,500 Class I 1,800
07.084 Pentan-3-one 1,600 Class I 1,800
07.178 3-Methylbutan-2-one 1,600 Class I 1,800
07.239 [R-(E)]-5-Isopropyl-8-methylnona-6,8-dien-2-one 1,600 Class I 1,800
09.304 sec-Heptyl isovalerate 3,900 Class I 1,800
09.323 sec-Butyl acetate 3,900 Class I 1,800
09.325 sec-Butyl butyrate 3,900 Class I 1,800
09.328 sec-Butyl formate 3,900 Class I 1,800
09.332 sec-Butyl hexanoate 3,900 Class I 1,800
09.386 sec-Hept-4(cis)-enyl acetate 3,900 Class I 1,800
09.388 sec-Heptyl acetate 3,900 Class I 1,800
09.391 sec-Heptyl hexanoate 3,900 Class I 1,800
09.604 Isopropyl decanoate 3,900 Class I 1,800
09.605 Isopropyl dodecanoate 3,900 Class I 1,800
09.606 Isopropyl hexadecanoate 3,900 Class I 1,800
09.608 Isopropyl octanoate 3,900 Class I 1,800
09.609 Isopropyl valerate 3,500 Class I 1,800
09.676 sec-Octyl acetate 3,900 Class I 1,800
09.880 (Z)-Hept-4-enyl-2 butyrate 3,900 Class I 1,800
09.926 Octan-3-yl formate 3,900 Class I 1,800
02.145 2,6-Dimethylocta-1,5,7-trien-3-ol 3,900 Class II 540
02.194 Octa-1,5-dien-3-ol 3,900 Class II 540
02.211 Undeca-1,5-dien-3-ol 3,900 Class II 540
07.072 6-Methylheptan-3-one 1,600 Class II 540
07.150 Decan-2-one 1,600 Class II 540
07.156 2,6-Dimethyloct-6-en-3-one (mixture of E and Z) 1,600 Class II 540
07.157 6,10-Dimethylundecan-2-one 1,500 Class II 540
07.158 Dodecan-2-one 1,600 Class II 540
07.160 Heptadecan-2-one 1,600 Class II 540
07.162 Hex-5-en-2-one 1,600 Class II 540
07.181 6-Methylheptan-2-one 1,600 Class II 540
07.185 3-Methylpentan-2-one 1,600 Class II 540
07.189 Nonan-4-one 1,600 Class II 540
07.198 Pseudo-ionone 1,600 Class II 540
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07.199 Tetradecan-2-one 1,600 Class II 540
07.201 Tridec-12-en-2-one 1,600 Class II 540
07.204 3,3,6-Trimethylhepta-1,5-dien-4-one 1,600 Class II 540
07.205 6,10,14-Trimethylpentadecan-2-one 1,500 Class II 540
07.236 (Z)-5-Octen-2-one 1,600 Class II 540
07.262 9-Decen-2-one 6,600 Class II 540
07.182 5-Methylheptan-3-one 1,600 Class II 540
02.131 But-3-en-2-ol 3,900 Class II 540
02.187 Non-1-en-3-ol 3,900 Class II 540
07.161 Hex-1-en-3-one 1,600 Class II 540
07.210 1-Nonene-3-one 1,600 Class II 540
mTAMDI: modiﬁed Theoretical Added Maximum Daily Intake.
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Appendix D – Metabolism
General information
The present ﬂavouring group evaluation consists of 53 candidate substances of which seven are
saturated aliphatic acyclic secondary alcohols [FL-nos: 02.077, 02.142, 02.148, 02.177, 02.182, 02.183
and 02.190]; seven are unsaturated aliphatic secondary alcohols [FL-nos: 02.124, 02.131, 02.145,
02.187, 02.194, 02.211 and 02.255] of which ﬁve contain a terminal double bond [FL-nos: 02.131,
02.145, 02.187, 02.194 and 02.211]; 13 are saturated aliphatic ketones [FL-nos: 07.072, 07.084,
07.150, 07.157, 07.158, 07.160, 07.178, 07.181, 07.182, 07.185, 07.189, 07.199 and 07.205], 10 are
unsaturated aliphatic ketones [FL-nos: 07.156, 07.161, 07.162, 07.198, 07.201, 07.204, 07.210, 07.236,
07.239 and 07.262] of which seven contain a terminal double bond [FL-nos: 07.161, 07.162, 07.201,
07.204, 07.210, 07.239 and 07.262] and 16 are esters of aliphatic acyclic secondary alcohols and linear
aliphatic carboxylic acids [FL-nos: 09.304, 09.323, 09.325, 09.328, 09.332, 09.386, 09.388, 09.391,
09.604, 09.605, 09.606, 09.608, 09.609, 09.676, 09.880 and 09.926]. The general metabolic reactions
that the candidate substances may be expected to undergo, and which are discussed below, are one
or several of the following:
• conjugation of secondary alcohols with glucuronic acid
• oxidation of secondary alcohols
• reduction of ketones
• oxidation of ketones
• oxidation of double bonds
• oxidation of terminal double bonds
• hydrolysis of esters.
A general discussion on the biotransformation of Saturated Aliphatic Acyclic Secondary Alcohols,
Ketones, and Related Saturated and Unsaturated Esters may be found in the reports from the 51st,
59th and 69th meetings of the JECFA (1999a, 2002a, 2009b). The discussions and conclusions related
to these supporting substances essentially apply also to the candidate substances. There is one
candidate substance 5-methylheptan-3-one [FL-no: 07.182] that may be oxidised to yield a neurotoxic
gamma-diketone and therefore it may potentially give rise to concern.
Absorption
In general, aliphatic secondary alcohols and ketones are expected to be rapidly absorbed in the
gastrointestinal tract (JECFA, 1999a).
Peak blood levels were obtained 1–2 h after dosing when isopropanol was given orally to rats as
well as when the same substance was administered intravenously to dogs (Lehman et al., 1945;
Nordmann et al., 1973). Peak blood levels were also obtained within 2 h when 1- and 2-propanol, or
1- and 2-isobutanol were given orally to human volunteers together with ethanol (Bonte et al., 1981).
In a pharmacokinetic experiment, 2-butanol (2.2 mL/kg bw or 1,776 mg/kg bw), 2-butanone
(2.1 mL/kg bw or 1,690 mg/kg bw) and 2,3-butanediol (0.68 mL/kg bw or 676 mg/kg bw),
respectively, were administered orally in aqueous solutions to male Sprague–Dawley rats. Peak blood
concentrations after administration of 0.95 mg/L 2-butanone were detected after 4 h and declined to
0.07 mg/mL after 18 h. The concentrations of the metabolites 2,3-butanediol, 2-butanol and
3-hydroxy-2-butanone peaked at 0.26, 0.033 and 0.027 mg/L at 18, 6 and 8 h, respectively, after
2-butanone administration. Total area under the curve (AUC) values for 2-butanone, 2,3-butanediol,
2-butanol and 3-hydroxy-2-butanone were 10,899  824, 3,863  238, 414  38 and 382  38 mg
h/L, respectively. Blood concentration after administration of 2-butanol peaked after 2 h at 0.59 mg/L
and declined to 0.05 mg/L after 16 h. The blood concentrations of 2-butanone, 3-hydroxy-2-butanone
and 2,3-butanediol rose to maximums after 8, 12 and 18 h and were 0.78, 0.04 and 0.21 mg/L,
respectively. Total AUC values were 3,254  258 mg h/L for 2-butanol, 9,868  566 for 2-butanone,
443  93 for 3-hydroxy-2-butanone and 3,167  503 mg h/L for 2,3-butanediol (Dietz et al., 1981).
Rats were administered 1 g/kg bw 2-pentanol, 3-pentanol and 3-methyl-2-butanol, via
intraperitoneal (IP) injection. The alcohols were eliminated within 13–16 h (Haggard et al., 1945).
Metabolism and elimination
Secondary alcohols
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Oxidation and glucuronic acid conjugation: Secondary alcohols may undergo oxidation to the
corresponding ketone. However, this reaction is generally unfavoured in vivo, since the alcohol is
removed from the equilibrium by conjugation with glucuronic acid, which represents the major
biotransformation pathway for secondary alcohols (Kasper and Henton, 1980; JECFA, 1999a).
Glucuronidation is a phase-II-reaction, which involves the transfer of glucuronic acid in an activated
form to functional groups of the substrate, in this case to the hydroxyl groups of the molecules. This
renders highly polar products, for which excretion is facilitated. The reaction is catalysed by
UDP-glucuronyl transferase, which exists in several isoforms with different substrate speciﬁcities. The
enzymes are located in the endoplasmic reticulum, and are found in most tissues including the liver.
The glucuronic acid conjugates are primarily excreted in the urine or bile, depending on the relative
molecular mass and the animal species. For the candidate secondary alcohols, the urine is expected to
be the main route of elimination.
Ketones
In addition to reduction and oxidation pathways, low molecular weight ketones (carbon chain length
< 5) may be excreted unchanged in expired air (Brown et al., 1987). In mammals, oral doses of volatile
ketones or their corresponding alcohols are mainly eliminated as the ketone in expired air. Lower
amounts are excreted in the urine (Haggard et al., 1945; Scopinaro et al., 1947; Schwartz, 1989).
In the rat, 2-pentanone in expired air was the major metabolite following administration of
2-pentanol by IP injection. Lower amounts of 2-pentanol were also exhaled and both metabolites were
detected in the urine (Haggard et al., 1945). Similarly, unchanged 2-pentanone administered orally to
dogs has been identiﬁed in the expired air (Schwartz, 1989).
Reduction of ketones: In general, the major metabolic pathway for the detoxiﬁcation and excretion of
aliphatic ketones involves reduction of the ketone to the corresponding secondary alcohol with
subsequent excretion as conjugate of glucuronic acid. This reaction is reversible under physiologic
conditions, but in vivo the secondary alcohols are removed from the equilibrium by conjugation to
glucuronic acid, as is stated above, and the reaction proceeds to form further secondary alcohols
(Felsted and Bachur, 1980; JECFA, 1999a). Reduction of aliphatic ketones is mediated by alcohol
dehydrogenase and NADH/NADPH-dependent cytosolic carbonyl reductases (Bosron and Li, 1980).
According to Felsted and Bachur (1980), the reaction catalysed by carbonyl reductase is
stereoselective and favours formation of the (S)-enantiomer of the alcohol (Felsted and Bachur, 1980).
In studies limited to the identiﬁcation of urinary glucuronide, relatively high single dose levels of a
homologous series of aliphatic secondary alcohols and ketones were administered individually by
gavage to rabbits. The urinary excretion of glucuronic acid conjugates was determined after 24 h
(Kamil et al., 1953). The substances, dose levels and average urinary output of glucuronide (UGAC)
are shown below in Table D.1.
Oxidation of ketones: Ketones may also be metabolised via omega- or omega-1-oxidation. Participation in
these pathways depends on chain length, position of the carbonyl function and dose (Dietz et al., 1981;
Topping et al., 1994).
Short chain ketones (C < 5) that contain a carbonyl function at the C-2 may undergo oxidation of
the terminal methyl group and subsequent oxidation to yield an alpha-keto carboxylic acid. As
intermediary metabolites, alpha-keto acids undergo oxidative decarboxylation to yield carbon dioxide
and a simple aliphatic carboxylic acid, which may be completely metabolised in the fatty acid pathway
and citric acid cycle. Alternatively, omega-oxidation may occur to yield a hydroxy-ketone, which may
Table D.1: The urinary excretion of glucuronic acid conjugates (UGAC, determined after 24 h) of
aliphatic secondary alcohols and ketones after administration by gavage to rabbits
(Kamil et al., 1953)






bw: body weight; UGAC: average urinary output of glucuronide.
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be further reduced to a diol, e.g. 2,3-butanediol from butanone, and excreted in the urine as a
glucuronic acid conjugate.
Longer chain aliphatic ketones (carbon chain length ≥ 5) are primarily metabolised via reduction,
but omega- and omega-1-oxidation are competing pathways at high concentrations (Dietz et al., 1981;
Topping et al., 1994).
Studies with speciﬁc substances: 4-Methylpentan-2-ol [FL-no: 02.183] and 4-hydroxy-4-methylpentan-
2-one were detected in serum after IP injection of 4-methylpentan-2-one in guinea pigs. The half-life
and clearance times of 4-methylpentan-2-one were 66 min and 6 h, respectively. 4-Hydroxy-4-
methylpentan-2-one was the principal metabolite and was cleared in 16 h. The concentration of 4-
methylpentan-2-ol [FL-no: 02.183] was too low for quantiﬁcation. 4-Methylpentan-2-one is metabolised
by reduction of the carbonyl group to form the secondary alcohol, 4-methylpentan-2-ol [FL-no:
02.183], and by oxidation at the omega-1 carbon atom to form the hydroxylated ketone, 4-hydroxy-4-
methylpentan-2-one (DiVincenzo et al., 1976).
Gamma-Diketone formation: Omega-1-oxidation of aliphatic ketones with special structural features
may yield neurotoxic gamma-diketones. The metabolic pathway includes oxidation of the omega-1-
carbon, ﬁrst to a hydroxy-ketone and then to a diketone. The gamma-spacing of the carbonyl
functions has been shown to be a prerequisite for neurotoxic effects, only ketones with this structural
feature may yield the neurotoxic metabolites. One of the candidate substances 5-methyl-3-heptanone
[FL-no: 07.182], may potentially be oxidised to a gamma-diketone 3-methyl-2,5-heptanedione.
Studies have shown that neurotoxicity of selected ketones is related to a common metabolic
pathway leading to the formation of a gamma-diketone, which is the metabolite that produces
neuropathy. The neurotoxic effects show a speciﬁc anatomic and morphological type of nerve
degeneration characterised by large multifocal axonal swellings, referred to as ‘giant-axonal’
neuropathy. Clinical symptomatology in humans includes bilaterally symmetrical paraesthesia, ‘pins and
needles’ feeling, and muscle weakness, primarily in arms and legs. Except for 3,6-octanedione, all
metabolic interconversions are oxidation of the omega-1-carbon, ﬁrst to a hydroxy-ketone and then to
a gamma-diketone. When the omega-carbon is oxidised in preference to the omega-1-carbon, no
gamma-diketone is formed (Topping et al., 1994).
Induction of clear and typical signs of neurotoxicity in male rats dosed with 5-methyl-3-heptanone
[FL-no: 07.182] in a subchronic study (IBM Corp., 1989) supported the hypothesis that a gamma-
diketone may be formed as toxic metabolite.
Data suggest that the neurotoxicity of the diketone decreases as chain length increases, possibly
owing to steric hindrance. However, chain length may not be important to some materials, as in the
case of 5-nonanone. Another factor modifying the neurotoxic potential of these substances is the
number and size of substituent groups located between the gamma-spaced carbonyls. Single methyl
groups on the carbons located between the carbonyl groups increase the potential neurotoxicity,
whereas two methyl groups positioned on one of the carbon atoms between the carbonyls eliminate
neurotoxicity (Topping et al., 1994).
Among the supporting substances, 3-heptanone [FL-no: 07.003], 2-methylheptan-3-one [FL-no:
07.240], 3-heptanol [FL-no: 02.044] and 3-heptyl acetate [FL-no: 09.924] are the only substances that
may be metabolised to yield neurotoxic gamma-diketones (Topping et al., 1994). The neurotoxicity for
these substances is observed only at high doses.
In a study reported as a meeting abstract, aliphatic ketones (hexane-2-one, pentane-3-one,
heptane-3-one, 4-methyl-2-pentanone and 3,3-dimethyl-2-butanone) were administered in drinking
water to female Wistar rats. It was concluded that administration of approximately 1 g/kg bw per day
of hexane-2-one for 120 days produced muscle weakness, atrophy and peripheral neuropathy. None of
the other ketones produced signiﬁcant neurological alterations (Homan and Maronpot, 1978).
In an oral gavage study Crl rats, two per group, were given 3-heptanone [FL-no: 07.003] (0.25, 0.5,
1 or 2 g/kg bw per day, for 5 days/week for 14 weeks. The highest dose group (approaching the LD50
value in rats = 2,760 mg/kg bw) was the only one developing treatment-related neuropathologic lesions
of typical ‘giant-axonal’ type. No neuropathology was observed in the lower dose groups (O’Donoghue
et al., 1984). This study determined that 3-heptanone has a low neurotoxic potential; however, when its
intake was combined with-methyl ethyl ketone, neurotoxic effects were potentiated, by stimulating
3-heptanone metabolism to 2,5-heptandione, a neurotoxic gamma-diketone (O’Donoghue et al., 1984).
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Oxidation of terminal double bonds in secondary alcohols and in ketones
Twelve of the candidate substances, but-3-en-2-ol, 2,6-dimethylocta-1,5,7-triene-3-ol, non-1-en-3-
ol, octa-1,5-dien-3-ol, undeca-1,5-dien-3-ol, hex-1-en-3-one, hex-5-en-2-one, tridec-12-en-2-one,
3,3,6-trimethylhepta-1,5-dien-4-one, 1-nonene-3-one, ([R-(E)]-5-isopropyl-8-methylnona-6,8-dien-2-
one and 9-decen-2-one [FL-nos: 02.131, 02.145, 02.187, 02.194, 02.211, 07.161, 07.162, 07.201,
07.204, 07.210, 07.239 and 07.262] have terminal double bonds. These double bonds may be oxidised
to the corresponding epoxides. Epoxides are highly reactive molecules, due to the large strain
associated with this three-membered ring structure, and they react easily with nucleophilic sites of
cellular macromolecules. However, epoxides will be conjugated with glutathione by glutathione S-
transferases or hydrolysed to diols by epoxide hydrolases. These two reactions can be considered to
be detoxications (Sanchez and Kauffman, 2010). 1-Alkenes are metabolised by P450 through both
double bond oxidation to the corresponding epoxide and allylic oxidation (Chiappe et al., 1998). The
rates of the two reactions measured with different P450 isoforms indicate that epoxide formation is
generally favoured (Chiappe et al., 1998).
Based on the low levels of intake of alkenones and alkenols characterised by a carbonyl or an
alcohol group in addition to the terminal double bond, it is expected that the detoxication reactions of
the formed epoxides (conjugation with glutathione or epoxide hydrolase mediated hydrolysis) would
not be saturated and would outweigh the rate of epoxide formation. The presence of the terminal
double bond is therefore not considered of concern under the intended conditions of use.
In addition to reduction and oxidation pathways, low molecular weight alcohols and ketones may
be excreted unchanged in expired air (Brown et al., 1987).
Ester hydrolysis
The aliphatic esters among the candidate substances are expected to be hydrolysed to their
component secondary alcohols and carboxylic acids. The carboxylesterase or esterase classes of
enzymes, the most important of which are the beta-esterases, catalyse ester hydrolysis (Heymann,
1980). In mammals, these enzymes occur within the body in most tissues including the gut lumen and
intestinal wall, but predominate in the hepatocytes (Heymann, 1980). The wide range of tissue
distribution and the multiplicity of esterases generally give rise to rapid hydrolysis of esters in vivo.
There are no hydrolysis studies on the candidate substances, but there are in vitro hydrolysis data
for structurally related esters.
In vitro hydrolysis studies of esters have been performed with speciﬁc carboxylesterase isoenzymes
isolated from pig and rat livers (Arndt and Krisch, 1973; Junge and Heymann, 1979). The isoenzyme I
exhibits an increase in enzyme binding (lower Km) and maximum velocity (Vmax) as the carbon chain
length of either the alcohol or carboxylic acid component of the substrate increases. It is also shown
that different isoenzymes show great differences in the hydrolysis rates. Isoenzyme V had an optimum
for the C-5 compound, while this isoenzyme exhibited a minimum activity with the butyl and pentyl
acetates. Results of in vitro studies indicate that the rate of hydrolysis of straight chain esters is
approximately 100 times faster than the rate of hydrolysis of branched-chain esters.
Incubation of isopropyl butanoate, isopropyl phenylacetate, isoamyl acetate and isoamyl
phenylacetate with pancreatin produced 40%, 50%, 20% and 100% hydrolysis, respectively, after 2 h
(Leegwater and van Straten, 1974a; Grundschober, 1977). Also, isoamyl acetate incubated with
intestinal mucosa homogenates obtained from pigs demonstrated complete hydrolysis (Leegwater and
van Straten, 1974b; Grundschober, 1977).
Esters formed from aliphatic secondary alcohols were hydrolysed to their corresponding alcohols
and carboxylic acids when incubated with liver homogenates or small intestinal homogenates obtained
from male Wistar albino rats, artiﬁcial gastric juice or artiﬁcial pancreatic juice with half-lives ranging
from less than one-second to several hours depending on the incubation medium (Gangolli and
Shilling, 1968; Longland et al., 1977). Rat liver homogenates and small intestinal preparations were
found to be much more efﬁcient than artiﬁcial pancreatic juice for hydrolysis of a variety of aliphatic
esters. Also, hydrolysis in simulated intestinal ﬂuid with pancreatin was much faster than in simulated
gastric juice (Longland et al., 1977).
The data on substances structurally related to the candidate substances indicate that hydrolysis is
the major pathway for the candidate substances that are esters of secondary alcohols, and that they
will be hydrolysed to their component alcohols and carboxylic acids within a relatively short time.
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Conclusion
In conclusion, it may be anticipated that 52 of the candidate substances (the seven saturated
aliphatic acyclic secondary alcohols [FL-nos: 02.077, 02.142, 02.148, 02.177, 02.182, 02.183 and
02.190], the seven unsaturated aliphatic secondary alcohols [FL-nos: 02.124, 02.131, 02.145, 02.187,
02.194, 02.211 and 02.255], the 12 of the 13 saturated aliphatic ketones [FL-nos: 07.072, 07.084,
07.150, 07.157, 07.158, 07.160, 07.178, 07.181, 07.185, 07.189, 07.199 and 07.205], the 10
unsaturated aliphatic ketones [FL-nos: 07.156, 07.161, 07.162, 07.198, 07.201, 07.204, 07.210, 07.236,
07.239 and 07.262] and the 16 esters of aliphatic acyclic secondary alcohols and linear aliphatic
carboxylic acids [FL-nos: 09.304, 09.323, 09.325, 09.328, 09.332, 09.386, 09.388, 09.391, 09.604,
09.605, 09.606, 09.608, 09.609, 09.676, 09.880 and 09.926]) will be metabolised to innocuous
substances at the estimated levels of intake, based on the MSDI approach, as ﬂavouring substances.
One candidate substance, 5-methyl-3-heptanone [FL-no: 07.182], may be oxidised to a potentially
neurotoxic gamma-diketone, 3-methyl-2,5-heptanedione.
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